InsiderTrades

Form 4 for CRBU Caribou Biosciences, Inc.

Accepted 2021-07-29 00:00:00 ET · period of report 2021-07-27 · accession 0000315066-21-001645 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2021-07-29 2021-07-27 CRBU FMR LLC See Remark 1 C - Cnv Deriv — +3.32M 770.5K New —
DMI 2021-07-29 2021-07-27 CRBU FMR LLC See Remark 1 C - Cnv Deriv — -1.83M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-07-27 C A 1,464,775 — 1,464,775 I Impresa Fund III Limited Partnership — — (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
2 Common Common Stock 2021-07-27 C A 17,572 — 17,572 I F-Prime Capital Partners Healthcare Advisors Fund IV LP — — (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
3 Common Common Stock 2021-07-27 C A 1,070,427 — 1,840,937 I F-Prime Capital Partners Healthcare Fund IV LP — — (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
4 Common Common Stock 2021-07-27 C A 770,510 — 770,510 I F-Prime Capital Partners Healthcare Fund IV LP — — (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
5 Derivative Series B Preferred Stock 2021-07-27 C D 423,823 — 0 I F-Prime Capital Partners Healthcare Fund IV LP — · — to — 770,510 Common Stock (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
6 Derivative Series A-1 Preferred Stock 2021-07-27 C D 805,707 — 0 I Impresa Fund III Limited Partnership — · — to — 1,464,775 Common Stock (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
7 Derivative Series A-1 Preferred Stock 2021-07-27 C D 9,666 — 0 I F-Prime Capital Partners Healthcare Advisors Fund IV LP — · — to — 17,572 Common Stock (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
8 Derivative Series A-1 Preferred Stock 2021-07-27 C D 588,794 — 0 I F-Prime Capital Partners Healthcare Fund IV LP — · — to — 1,070,427 Common Stock (F1) On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.